Hypertrophic Heart Disease Clinical Trials

Cedars-Sinai Heart Institute is currently conducting the following Hypertrophic Heart Disease clinical trials:

Long-term Outcomes of Percutaneous Alcohol Septal Ablation for Patients with Hypertrophic Cardiomyopathy

Long-term Outcomes of Percutaneous Alcohol Septal Ablation for Patients with Hypertrophic Cardiomyopathy

Principal Investigator: Raj Makkar, MD

IRB Approval Number: 9819

Contact: Michelle Domingo (310) 423-3875

Status: Data Analysis

Summary: The treatment of hypertrophic obstructive cardiomyopathy (HOCM) with alcohol septal ablation (ASA) has received increasing interest.  However, there is a paucity of data on the long-term outcome of this treatment for patients who are symptomatic with this condition.  Therefore, the main objective of this study is to evaluate the long-term outcomes of patients who underwent alcohol septal ablation at Cedars-Sinai Medical Center for hypertrophic obstructive cardiomyopathy.  

Android app on Google Play